File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines

TitleBaseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines
Authors
Issue Date25-Sep-2023
PublisherSpringer Nature
Citation
Signal transduction and targeted therapy, 2023, v. 8, n. 1 How to Cite?
Abstract

The role of gut microbiota in modulating the durability of COVID-19 vaccine immunity is yet to be characterised. In this cohort study, we collected blood and stool samples of 121 BNT162b2 and 40 CoronaVac vaccinees at baseline, 1 month, and 6 months post vaccination (p.v.). Neutralisation antibody, plasma cytokine and chemokines were measured and associated with the gut microbiota and metabolome composition. A significantly higher level of neutralising antibody (at 6 months p.v.) was found in BNT162b2 vaccinees who had higher relative abundances of Bifidobacterium adolescentis, Bifidobacterium bifidum, and Roseburia faecis as well as higher concentrations of nicotinic acid (Vitamin B) and γ-Aminobutyric acid (P < 0.05) at baseline. CoronaVac vaccinees with high neutralising antibodies at 6 months p.v. had an increased relative abundance of Phocaeicola dorei, a lower relative abundance of Faecalibacterium prausnitzii, and a higher concentration of L-tryptophan (P < 0.05) at baseline. A higher antibody level at 6 months p.v. was also associated with a higher relative abundance of Dorea formicigenerans at 1 month p.v. among CoronaVac vaccinees (Rho = 0.62, p = 0.001, FDR = 0.123). Of the species altered following vaccination, 79.4% and 42.0% in the CoronaVac and BNT162b2 groups, respectively, recovered at 6 months. Specific to CoronaVac vaccinees, both bacteriome and virome diversity depleted following vaccination and did not recover to baseline at 6 months p.v. (FDR < 0.1). In conclusion, this study identified potential microbiota-based adjuvants that may extend the durability of immune responses to SARS-CoV-2 vaccines.


Persistent Identifierhttp://hdl.handle.net/10722/339081
ISSN
2023 Impact Factor: 40.8
2023 SCImago Journal Rankings: 8.737
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorPeng, Y-
dc.contributor.authorZhang, L-
dc.contributor.authorMok, CKP-
dc.contributor.authorChing, JYL-
dc.contributor.authorZhao, SL-
dc.contributor.authorWong, MKL-
dc.contributor.authorZhu, J-
dc.contributor.authorChen, CK-
dc.contributor.authorWang, SL-
dc.contributor.authorYan, S-
dc.contributor.authorQin, BY-
dc.contributor.authorLiu, YZ-
dc.contributor.authorZhang, X-
dc.contributor.authorCheung, CP-
dc.contributor.authorCheong, PK-
dc.contributor.authorIp, KL-
dc.contributor.authorFung, ACH-
dc.contributor.authorWong, KKY-
dc.contributor.authorHui, DSC-
dc.contributor.authorChan, FKL-
dc.contributor.authorNg, SC-
dc.contributor.authorTun, HM-
dc.date.accessioned2024-03-11T10:33:45Z-
dc.date.available2024-03-11T10:33:45Z-
dc.date.issued2023-09-25-
dc.identifier.citationSignal transduction and targeted therapy, 2023, v. 8, n. 1-
dc.identifier.issn2095-9907-
dc.identifier.urihttp://hdl.handle.net/10722/339081-
dc.description.abstract<p>The role of gut microbiota in modulating the durability of COVID-19 vaccine immunity is yet to be characterised. In this cohort study, we collected blood and stool samples of 121 BNT162b2 and 40 CoronaVac vaccinees at baseline, 1 month, and 6 months post vaccination (p.v.). Neutralisation antibody, plasma cytokine and chemokines were measured and associated with the gut microbiota and metabolome composition. A significantly higher level of neutralising antibody (at 6 months p.v.) was found in BNT162b2 vaccinees who had higher relative abundances of Bifidobacterium adolescentis, Bifidobacterium bifidum, and Roseburia faecis as well as higher concentrations of nicotinic acid (Vitamin B) and γ-Aminobutyric acid (P &lt; 0.05) at baseline. CoronaVac vaccinees with high neutralising antibodies at 6 months p.v. had an increased relative abundance of Phocaeicola dorei, a lower relative abundance of Faecalibacterium prausnitzii, and a higher concentration of L-tryptophan (P &lt; 0.05) at baseline. A higher antibody level at 6 months p.v. was also associated with a higher relative abundance of Dorea formicigenerans at 1 month p.v. among CoronaVac vaccinees (Rho = 0.62, p = 0.001, FDR = 0.123). Of the species altered following vaccination, 79.4% and 42.0% in the CoronaVac and BNT162b2 groups, respectively, recovered at 6 months. Specific to CoronaVac vaccinees, both bacteriome and virome diversity depleted following vaccination and did not recover to baseline at 6 months p.v. (FDR &lt; 0.1). In conclusion, this study identified potential microbiota-based adjuvants that may extend the durability of immune responses to SARS-CoV-2 vaccines.</p>-
dc.languageeng-
dc.publisherSpringer Nature-
dc.relation.ispartofSignal transduction and targeted therapy-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleBaseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41392-023-01629-8-
dc.identifier.scopuseid_2-s2.0-85172399775-
dc.identifier.volume8-
dc.identifier.issue1-
dc.identifier.eissn2059-3635-
dc.identifier.isiWOS:001071191700002-
dc.identifier.issnl2059-3635-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats